Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx is expected to see a positive outlook in the long-term due to the company's strong product pipeline, with its Zephyr Valve and LungTraX Platform showing promising potential in the treatment of severe emphysema. Additionally, the company's cost restructuring initiatives and increasing international revenue are expected to improve profitability and help mitigate risk factors. In the short-term, the company may face challenges in the U.S. due to the current commercial reset, but its partnership with hospitals and increasing evidence of same-store productivity could support growth.

Pulmonx is currently facing multiple challenges, as evident from their declining revenue from both the U.S. and international markets. In addition, their cash balance has decreased significantly over the past year, and their operating expenses remain high, leading to a narrow net loss. These issues, along with various risk factors, suggest that the company's outlook is negative in the near term, with limited growth potential.